You are here: Home :: Keyword index :: evo bis Hab :: fibrin network - filtered back-projection fibrinolysis

Items for "fibrinolysis"

Clot structure modification by fondaparinux and consequence on fibrinolysis: A new mechanism of antithrombotic activity

Fondaparinux is a synthetic pentasaccharide consisting of the minimal sequence of heparin which interacts with antithrombin (AT)...

Keywords: Fondaparinux, clot structure, fibrinolysis, fibrin network

01/2007 | Thrombosis and Haemostasis, Schattauer

Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA

Clinical as well as experimental evidence suggests that vascular overexpression of plasminogen activator inhibitor (PAI)-1, the primary physiological inhibitor of both urokinase and tissuetype plasminogen activator, may be involved in the pathophysiology of atherosclerosis and cardiovascular disease...

Keywords: Cell adhesion, fibrinolysis, Endothelial cells, plasminogen activator inhibitor-1, RNA interference

05/2006 | Thrombosis and Haemostasis, Schattauer

Role of fibrinolysis and interventional therapy for acute venous thromboembolism

The initial goals of treatment for venous thromboembolism (VTE) are usually achieved with anticoagulation...

Keywords: deep vein thrombosis, pulmonary embolism, fibrinolysis, thrombolysis, inferior vena cava filter

09/2006 | Thrombosis and Haemostasis, Schattauer

Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models. Sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI)

In this study, the in-vitro fibrinolytic efficacy of Tenecteplase, Amediplase and scu-PA was investigated in different external lysis models by measuring the lysis of human plasma clots after the addition of the plasminogen activators (PAs) to the surrounding plasma...

Keywords: TAFI, plasminogen activator, fibrinolysis, thrombolysis, Amediplase, Tenecteplase

09/2006 | Thrombosis and Haemostasis, Schattauer

Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis

Splanchnic vein thrombosis (SVT) has been associated with a hypercoagulable state. Thrombin-activatable fibrinolysis inhibitor (TAFI) may contribute to a hypercoagulable state, and therefore we were interested in the role of TAFI in SVT...

Keywords: Thrombin-activatable fibrinolysis inhibitor, Budd-Chiari syndrome, portal vein thrombosis, single nucleotide polymorphism, splanchnic vein thrombosis, inflammation, fibrinolysis

00/0000 | Thrombosis and Haemostasis, Schattauer

Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation of ALK-1/endoglin pathway in endothelial cells

Recurrent epistaxis is the most frequent clinical manifestation of hereditary haemorrhagic telangiectasia (HHT)...

Keywords: Endothelial cells, HHT, endoglin, ALK-1, tranexamic acid, fibrinolysis

00/0000 | Thrombosis and Haemostasis, Schattauer

Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development

Thrombin is a pivotal enzyme formed in the coagulation cascade and an important and potent platelet activator...

Keywords: blood coagulation, clot elasticity, fibrinolysis, PAR receptors

03/2007 | Thrombosis and Haemostasis, Schattauer

Haemostatic activation in post-menopausal women taking low-dose hormone therapy: Less effect with transdermal administration?

Hormone therapy (HT) increases the risk of cardiovascular and thromboembolic disease in post-menopausal women...

Keywords: Transdermal hormone therapy, Coagulation, fibrinolysis, menopause

04/2007 | Thrombosis and Haemostasis, Schattauer

The snake venom metalloproteases berythractivase and jararhagin activate endothelial cells

PIII snake venom metalloproteases (SVMPs) are metalloproteases structurally related to ADAMs (a disintegrin and metalloprotease human family of proteins)...

Keywords: Apoptosis, berythractivase, Coagulation, endothelial cell, fibrinolysis, jararhagin, prothrombin activator, snake venom metalloproteases (SVMP)

04/2005 | Biological Chemistry, Walter de Gruyter

Monitoring of fibrinolysis parameters during myocardial revascularization according to type of procedure

The aim of the study was to assess the effect of cardiothoracic surgery on the dynamics of plasminogen, D-dimers and plasminogen activator inhibitor (PAI-I) during the first 24 h after surgery...

Keywords: cardiopulmonary bypass, D-dimers, fibrinolysis, plasminogen activator inhibitor (PAI-I), plasminogen

01/2005 | Clinical Chemical Laboratory Medicine, Walter de Gruyter

In vitro inhibition of fibrinolysis by apolipoprotein(a) and lipoprotein(a) is size- and concentration-dependent

Lipoprotein(a) (Lp(a)) is considered an independent risk factor for atherosclerotic heart and circulatory diseases...

Keywords: fibrinolysis, inhibition, lipoprotein(a), Phenotype, thrombosis

09/2004 | Clinical Chemical Laboratory Medicine, Walter de Gruyter

Nitration of human plasminogen by RAW 264.7 macrophages reduces streptokinase-induced plasmin activity

Despite many years of study, clinical trials of new drugs to prevent thrombosis have often been disappointing...

Keywords: atherosclerosis, diabetes, fibrinolysis, nitrosative stress, peroxynitrite, phagocytes

02/2006 | Clinical Chemical Laboratory Medicine, Walter de Gruyter

Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability

Background: Measurement of some haemostatic factors and products formed during activation of haemostasis seems to be promising in the determination of hypercoagulability.

Methods: The fibrinolytic variables euglobulin clot lysis time, tissue-type plasminogen activator, plasminogen activator inhibitor-1 and the haemostasis activation markers prothrombin fragment 1+2, thrombin-antithrombin complex and D-dimer were determined in 101 apparently healthy men and women aged 20–92 years (58±18 years, mean±SD) to establish variability due to several demographic, behavioural and metabolic factors.

Results: None of the fibrinolytic variables were affected by smoking, while tissue-type plasminogen activator antigen was significantly lower in women compared to men...

Keywords: D-dimer, fibrinolysis, plasminogen activator inhibitor-1, prothrombin fragment 1+2, thrombin-antithrombin complex, Tissue-type plasminogen activator

01/2007 | Clinical Chemical Laboratory Medicine, Walter de Gruyter

Coagulation-fibrinolysis is more enhanced in twin than in singleton pregnancies

Aims: To examine whether coagulation-fibrinolysis in late pregnancy in women with twin pregnancies is more pronounced than in women with singleton pregnancies.

Patients and methods: The plasma levels of D-dimer, fibrinogen/fibrin degradation products (FDP), and fibrinogen, the platelet count, and the antithrombin activity were assessed from 3 weeks before delivery until postpartum day 7 in 48 women (24 singleton and 24 twin pregnancies) without preeclampsia who underwent cesarean sections.

Results: Women with singleton or twin pregnancies gave birth at 37.3±1.2 weeks or 35.2±1.4 weeks, respectively...

Keywords: Antithrombin activity, Coagulation, D-dimer, fibrinolysis, twin

10/2006 | Journal of Perinatal Medicine, Walter de Gruyter

TAFI: regulating the cross talk between coagulation and fibrinolysis TAFI: Regulierung der Wechselwirkung zwischen Gerinnung und Fibrinolyse

Thrombin activates thrombin-activatable fibrinolysis inhibitor (TAFI) that removes C-terminal lysines or arginines...

Keywords: Carboxypeptidase, Fibrinolyse, Gerinnung, Thrombin-aktivierbarer Fibrinolyseinhibitor

12/2005 | LaboratoriumsMedizin, Walter de Gruyter

Publisher and Institutes

You are here: Home :: Keyword index :: evo bis Hab :: fibrin network - filtered back-projection fibrinolysis

Items for "fibrinolysis"